ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.780
+0.090 (5.33%)
At close: Mar 6, 2026, 4:00 PM EST
1.730
-0.050 (-2.81%)
After-hours: Mar 6, 2026, 7:38 PM EST
ProQR Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ProQR Therapeutics stock have an average target of 7.67, with a low estimate of 4.00 and a high estimate of 12. The average target predicts an increase of 330.90% from the current stock price of 1.78.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 4, 2025.
Analyst Ratings
The average analyst rating for ProQR Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 3 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +124.72% | Nov 4, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +124.72% | Aug 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $8 | Buy | Reiterates | $8 | +349.44% | Jun 27, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $8 | Buy | Reiterates | $8 | +349.44% | Jun 27, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $9 | Buy | Maintains | $15 → $9 | +405.62% | May 13, 2025 |
Financial Forecast
Revenue This Year
15.37M
from 19.55M
Decreased by -21.36%
Revenue Next Year
18.21M
from 15.37M
Increased by 18.45%
EPS This Year
-0.44
from -0.32
EPS Next Year
-0.56
from -0.44
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 22.7M | 58.8M | ||||
| Avg | 15.4M | 18.2M | ||||
| Low | 11.0M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 15.9% | 282.6% | ||||
| Avg | -21.4% | 18.4% | ||||
| Low | -43.8% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.40 | -0.39 | |
| Avg | -0.44 | -0.56 | |
| Low | -0.48 | -0.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.